The Missing Discipline in Prostate Cancer Care: Precision Medicine
Why AI-enabled integration of multidisciplinary expertise may be the key to optimal survivorship for men with advanced prostate cancer.
As our understanding of prostate cancer has expanded dramatically, knowledge has become increasingly siloed across disciplines including urology, medical oncology, radiation oncology, genomics, immunology, pathology, imaging, and supportive care.
Get Mark Perloe’s stories in your inbox
Join Medium for free to get updates from this writer.
While this growth in expertise has driven important advances, it has also fragmented care. Too often, men with advanced or high-risk prostate cancer find themselves navigating a maze of partially correct and sometimes competing treatment narratives. What emerges can be a patchwork approach to care rather than a truly personalized strategy.
The problem is compounded by economic pressures that favor standardized treatment pathways. Yet prostate cancer is not a single disease. Each patient’s tumor biology, genomic profile, immune environment, comorbidities, and social circumstances are unique and can significantly influence outcomes.
What is needed is not simply better treatments, but a new diagnostic discipline focused on integrating all of this information before treatment decisions are made.
Rather than directing patients from specialist to specialist in search of the latest intervention, we should first seek a comprehensive understanding of the individual patient and the unique characteristics of his disease. Shared decision-making depends on the ability to synthesize enormous amounts of complex data into a coherent, patient-centered strategy.
This is where artificial intelligence may become transformative.
AI, Patients, caregivers, and advocates have an important role to play in accelerating this transformation. We should be asking not only what treatment comes next, but whether all available information has been integrated into the decision. Have genomic findings, biomarkers, imaging, immune factors, comorbidities, quality-of-life considerations, and patient goals been considered together? By demanding more comprehensive, data-driven, and patient-centered care, we can help move prostate cancer treatment beyond fragmented decision-making and toward a future where precision medicine, supported by multidisciplinary expertise and AI, becomes the standard for optimal survivorship.I is not a replacement for clinicians. Rather, it can serve as a force multiplier for multidisciplinary expertise. By helping integrate genomic data, biomarkers, imaging findings, clinical outcomes, co-morbidities, and emerging scientific evidence, AI can reveal patterns and opportunities that are difficult for any individual specialist to recognize alone.
The future of prostate cancer care may lie in a collaborative model where AI assists teams of specialists in translating mountains of fragmented information into actionable knowledge tailored to each patient.
Precision medicine is ultimately about organizing knowledge around the individual rather than fitting the individual into a predefined treatment pathway. The partnership between AI and multidisciplinary clinical expertise may offer our clearest path toward longer survival, better quality of life, and optimal survivorship.
